- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02826447
Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C (IMMHoTHep)
ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Hepatitis C virus (HCV) is a blood-borne virus and its major route of transmission include blood transfusion, medical injection and procedure, and injecting drug use. In Egypt, the origin of the HCV epidemic has been attributed to a mass treatment of schistosomiasis between 1960 and 1984, when intravenous injections with antimony salts were given to 3-5 million people older than 6 years of age. Insufficient sterilization of needles and syringes was considered to be responsible for HCV transmission at that time. In order to control the spread of HCV in Egypt, the Egyptian Ministry of Health and Population established the National Committee for the Control of Viral Hepatitis. By 2008, this committee developed a National Control Strategy for Viral Hepatitis which has recommended prevention and education campaigns targeting general population and also healthcare workers (HCW). In their occupational environment, HCWs are frequently exposed to multiple blood-borne pathogens, including HCV. Several risk factors for HCV acquisition among patients and HCWs within a hospital ward have been identified, including a high prevalence of HCV infection in the ward, understaffing, workplace characteristic, and human factors such as inexperience or unfamiliar with equipment. However, to the investigators' knowledge, the overall risk of HCV acquisition associated with hospital stay has never been evaluated in Egypt. Also, control measures to reduce the risk of HCV transmission in hospital settings, based on a global assessment of healthcare provider logistics and performance, have never been proposed in Egypt.
In this project, the investigators assume that HCV will be transmitted to both hospital staff and patients. Given the slow dynamics of the HCV epidemic, the investigators further hypothesize that, in the short term, the prevalence of HCV viremia among patients will be constant. Therefore, the investigators are led to conclude that HCV transmission risk may be inferred from a detailed description of individual trajectories of patients or staff within the hospital.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
-
Cairo, Egypten
- Rekruttering
- Ain Shams University Teaching Hospital
-
Kontakt:
- Ghada A Ismail, Professor
- E-mail: ghada.ismail@yahoo.com
-
Ledende efterforsker:
- Wagida Anwar, Professor
-
Underforsker:
- Ghada A Ismail, Professor
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
500 patients staying at least 24 hours in one of the following departments of the Ain Shams University Teaching Hospital: surgery, internal medicine, gynecology/obstetrics and toxicology.
50 healthcare workers working in one of departments cited above.
Beskrivelse
Inclusion Criteria for patients:
- Aged 21 years or older
- Staying in the hospital more than 24 hours
- Provided a written informed consent to participate
Inclusion Criteria for healthcare workers:
- Aged 21 or older
- Provided a written informed consent to participate
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Patients
500 patients who are going to be hospitalized for at least 24 hours at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
|
|
Healthcare workers
50 healthcare workers working at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Per-day risk of HCV acquisition for a hospitalized patient
Tidsramme: 1 day
|
Per-day risk of HCV acquisition for a hospitalized patient
|
1 day
|
|
Per-week risk of HCV acquisition for a healthcare worker through occupational blood exposure
Tidsramme: 1 week
|
Per-week risk of HCV acquisition for a healthcare worker through occupational blood exposure
|
1 week
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Estimation of the number of HCV acquisitions among patients and HCWs prevented over a 1-year period following the implementation of various control strategies, using a mathematical modeling approach
Tidsramme: 1 year
|
Estimation of the number of HCV acquisitions among patients and HCWs prevented over a 1-year period following the implementation of various control strategies,
|
1 year
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Laura Temime, Professor, Conservatoire national des Arts et Métiers
- Ledende efterforsker: Wagida Anwar, Professor, Ain shams university
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ANRS 12320
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Exposure to Hepatitis C Virus
-
AbbVieAfsluttetHepatitis C virus | Kronisk hepatitis C-virus
-
AbbVieAfsluttetKronisk hepatitis C | Hepatitis C virus | Genotype 3 hepatitis C-virus
-
AbbVieAfsluttetHepatitis C virus | Kronisk hepatitis C-virus
-
National Taiwan University HospitalHoffmann-La RocheAfsluttetSamtidig infektion med hepatitis B-virus og hepatitis C-virus | Monoinfektion med hepatitis C-virusKina
-
University of California, IrvineUniversity of California, Los Angeles; National Institute on Minority Health...AfsluttetHepatitis C virus (HCV) infektionForenede Stater
-
AbbVieRekrutteringHepatitis C-virus (HCV)Canada
-
Xiangya Hospital of Central South UniversityAktiv, ikke rekrutterendeHepatitis C-virus (HCV)Kina
-
Merck Sharp & Dohme LLCAfsluttet
-
Gilead SciencesAfsluttetHepatitis C virusKorea, Republikken
-
Bristol-Myers SquibbAfsluttetHepatitis C virusKorea, Republikken, Taiwan, Den Russiske Føderation